Amicus, Brammer Bio Enter Gene Therapy Devt. and Mfg. Collaboration

Amicus Therapeutics has entered a manufacturing collaboration with Brammer Bio, now a part of contract development and manufacturing organization (CDMO) Thermo Fisher Scientific. Thermo’s late-stage clinical and commercial-scale capabilities provides Amicus with immediate clinical and commercial manufacturing capabilities and capacity for the Amicus intrathecal AAV Batten disease gene therapy programs. Amicus has also established a plasmid supply network together with multiple long-term supply agreements from industry leading plasmid suppliers to support advancement of all current gene therapy pipeline programs in the Amicus portfolio.
 
Batten disease programs: current research and development production technologies and capabilities related to the Amicus preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other potential Batten disease programs are being transferred to and developed at Thermo Fisher’s viral vector services business.
 
CLN6 Batten disease gene therapy: the existing process for the CLN6 Batten disease gene therapy is being transferred to Thermo Fisher and undergoing a similar GMP process for clinical and commercial-scale manufacturing and supply.
 
Broader portfolio: Thermo Fisher and Amicus to collaborate to develop platform manufacturing capabilities to support the broader portfolio of AAV gene therapy programs
 
"As we advance one of the industry’s leading gene therapy pipelines, our partnership with Brammer Bio, now part of Thermo Fisher, is a significant next step in fulfilling our manufacturing strategy so that we can deliver novel gene therapies to more people living with rare genetic diseases as quickly as possible, especially in devastating diseases like Batten’s, where time is of the essence," said John F. Crowley, chairman and chief executive officer, Amicus. "With our decade of experience in biologics manufacturing, we understand the importance and complexities of technology transfer during the drug development process. We look forward to embedding our Amicus team and other strategic partners in the tech transfer process to Thermo Fisher, and to further augmenting our manufacturing capabilities and partnerships across our entire gene therapy portfolio."
 
Chris Murphy, vice president and general manager, viral vector services, Thermo Fisher Scientific, said, "We are thrilled to begin working with Amicus and to contribute to the successful development of their gene therapy pipeline. We see this as a strong strategic relationship to enable manufacturing of a deep gene therapy pipeline across various stages of development for people with devastating genetic diseases. These therapies have the potential to transform patients' lives and, as an organization, we are delighted to support partners such as Amicus as they advance tomorrow's potential medicines." 

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com